Blindness

Fundus Camera Market to Reach $710.20 Mn, Globally, by 2030 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Monday, September 6, 2021

PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, " Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 20212030."

Key Points: 
  • PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, " Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 20212030."
  • According to the report, the global fundus camera market generated $445.60 million in 2020, and is expected to garner $710.20 million by 2030, witnessing a CAGR of 4.5% from 2021 to 2030.
  • For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/13448
    Surge in prevalence of chronic eye diseases and favorable government regulations drive the growth of the global fundus camera market.
  • However, high costs of initial investment and lack of awareness in low-income countries hinder the market growth.

Fundus Camera Market to Reach $710.20 Mn, Globally, by 2030 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Monday, September 6, 2021

PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, "Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030." According to the report, the global fundus camera market generated $445.60 million in 2020, and is expected to garner $710.20 million by 2030, witnessing a CAGR of 4.5% from 2021 to 2030.

Key Points: 
  • - Surge in prevalence of chronic eye diseases and favorable government regulations drive the growth of the global fundus camera market.
  • PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, " Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 20212030."
  • According to the report, the global fundus camera market generated $445.60 million in 2020, and is expected to garner $710.20 million by 2030, witnessing a CAGR of 4.5% from 2021 to 2030.
  • For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/13448
    Surge in prevalence of chronic eye diseases and favorable government regulations drive the growth of the global fundus camera market.

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa

Retrieved on: 
Wednesday, August 4, 2021

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).
  • Retinitis pigmentosa is a serious and incurable sight-threatening disease that represents a major unmet need in the field of ophthalmology, stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.
  • "ADX-2191 has now received orphan designations for three distinct clinical indications, highlighting the broad platform potential of ADX-2191 to treat an array of rare retinal disorders.
  • Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases.

New survey reveals Canadians short sighted when it comes to their eye health

Retrieved on: 
Tuesday, August 3, 2021

"The survey revealed that there is room to improve Canadians' education on proper eye care and safety," says Colin Mann, President of the Canadian Ophthalmological Society.

Key Points: 
  • "The survey revealed that there is room to improve Canadians' education on proper eye care and safety," says Colin Mann, President of the Canadian Ophthalmological Society.
  • "While the majority of Canadians are concerned with their eye health overall, some of the misconceptions they have could leave them more vulnerable to one of the four major eye diseases."
  • While these eye diseases are more common amongst those aged 60+, eye care and regular checkups are vital throughout all stages of life.
  • Six in ten Canadians are unaware that many eye diseases, including glaucoma, won't always present symptoms until they are at an advanced stage.

AGTC to Participate at Upcoming Investor Conferences

Retrieved on: 
Monday, August 2, 2021

2021 Wedbush PacGrow Healthcare Virtual Conference (August 10-11, 2021)

Key Points: 
  • 2021 Wedbush PacGrow Healthcare Virtual Conference (August 10-11, 2021)
    Ms. Washer will participate in a panel discussion entitled: Only Have Eyes For You - Ophthalmic Gene Therapy at 8:00 a.m.
  • Audio webcasts of the presentations at the Wedbush and H.C. Wainwright conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations .
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

Glaucoma Epidemiology Forecasts to 2030: 10 Year Forecasts, 7MM Coverage, Total Prevalent Cases and Glaucoma Patients by Age Group - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021

The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period.

Key Points: 
  • The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period.
  • Among the European five countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,042,465 cases, followed by Italy and France in 2020.
  • Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalent Population of Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma.

LENSAR to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Retrieved on: 
Thursday, July 29, 2021

LENSAR, Inc. (NASDAQ: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Companys second quarter 2021 financial results will be released before market open on Thursday, August 5, 2021.

Key Points: 
  • LENSAR, Inc. (NASDAQ: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Companys second quarter 2021 financial results will be released before market open on Thursday, August 5, 2021.
  • LENSARs management will host a conference call and webcast at 8:30 am ET on Thursday, August 5, 2021 to discuss the financial results and recent corporate highlights.
  • To participate by telephone, please dial (833) 312-1363 (Domestic) or (236) 712-2498 (International).
  • To access the live webcast, please go to the Investors section of LENSARs website at www.lensar.com .

FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

Retrieved on: 
Thursday, July 29, 2021

Therefore, we hope faricimab will become a new treatment option for millions of people living with wet AMD and DME.

Key Points: 
  • Therefore, we hope faricimab will become a new treatment option for millions of people living with wet AMD and DME.
  • Faricimab is the first injectable eye medicine to achieve this length of time between treatments in Phase III studies for wet AMD and DME.
  • The European Medicines Agency has also validated the faricimab Marketing Authorization Application for the treatment of wet AMD and DME.
  • Affecting approximately 750,000 people in the United States, diabetic macular edema (DME) is a vision-threatening complication of diabetic retinopathy (DR).

Nancy Lynne Harris is recognized by Continental Who's Who

Retrieved on: 
Thursday, July 22, 2021

EUGENE, Ore., July 22, 2021 /PRNewswire/ -- Nancy Lynne Harris is being recognized by Continental Who's Who as Trusted Spiritual Teacher for her sensational work in the field of Spiritual Healing.

Key Points: 
  • EUGENE, Ore., July 22, 2021 /PRNewswire/ -- Nancy Lynne Harris is being recognized by Continental Who's Who as Trusted Spiritual Teacher for her sensational work in the field of Spiritual Healing.
  • Ms. Harris is the owner and founder of GodSpirits United LLC, where she provides healing energy treatments and monthly educational workshops.
  • With over 25 years of expertise in the field, Ms. Harris specializes in treating depression and glaucoma.
  • When giving educational workshops, Ms. Harris has participants think positive thoughts to bathe bodily organs in nourishing healthy fluid.

Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Retrieved on: 
Thursday, July 22, 2021

FARMINGTON HILLS, Mich., July 22, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled “APE1/Ref-1 as a Novel Target for Retinal Disease”.

Key Points: 
  • APX3330 represents the Ref-1 programs lead compound, with pipeline candidates APX2009 and APX2014 that could be formulated for intravitreal sustained release delivery.
  • In five Phase 2 studies involving over 300 patients, APX3330 given oral (systemically) was well tolerated with no significant safety issues identified.
  • The primary endpoint for the ZETA-1 trial is the Early Treatment Diabetic Retinopathy Score (ETDRS) diabetic retinopathy severity score (DRSS).
  • Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia.